Roche Holding (ROG.SW) Aandeel Koers

Roche Holding AG is a Swiss company active in the pharmaceutical and diagnostics sectors. Founded in 1896 by Fritz Hoffmann-La Roche in Basel, it is today one of the world’s largest pharmaceutical corporations. Roche’s business model is based on the research, development, and distribution of innovative medicines as well as diagnostics for the early detection, diagnosis, and treatment of diseases. Roche’s customers are primarily physicians, hospitals, and laboratories. Roche operates through three divisions: Pharma, Diagnostics, and Genentech. The Pharma division is responsible for the development and marketing of prescription drugs. The Diagnostics division offers a wide range of products for disease diagnosis, including instruments and tests for cancer, blood disorders, and infectious diseases. The Genentech division focuses on the development of biotechnological medicines. Roche is renowned for its substantial investment in research into new medicines. The company has played a significant role in the history of drug development and has launched many life-saving medications over recent decades, including treatments for cancer and multiple sclerosis. The company is also known for its innovative diagnostic products. Roche has developed numerous tests for the early detection of diseases, which are used by physicians and laboratories worldwide. Roche employs approximately 94,000 people globally across more than 100 countries, with roughly half of its workforce based in Switzerland. The company is listed on the Swiss Stock Exchange (SIX: ROG) and has a market capitalization of approximately 300 billion Swiss francs. Among Roche’s most well-known products are the cancer drug Avastin, the multiple sclerosis medication Ocrevus, and the diabetes medication RoActemra. In the diagnostics segment, Roche offers a broad portfolio of products, including tests for HIV, hepatitis, and malaria. In recent years, Roche has expanded its activities into new therapeutic areas such as immunotherapies and gene therapies. The company maintains a strong pipeline of new medicines and diagnostics scheduled for launch in the coming years. Since its founding, Roche has played a pivotal role in drug development and diagnostics. With its robust research investments and extensive product portfolio, the company is poised to continue playing a key role in the healthcare industry.